site stats

Recursion therapeutics stock

WebApr 12, 2024 · 5 analysts have issued 12-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price forecasts range from $8.00 to $20.00. On … WebRecursion Pharmaceuticals is an automated drug discovery platform. The company combines experimental biology, automation, and artificial intelligence in a parallel system …

Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (…

WebApr 14, 2024 · Esperion Therapeutics Inc (ESPR) stock is trading at $1.21 as of 11:29 AM on Friday, Apr 14, a drop of -$0.14, or -10.37% from the previous closing price of $1.35. The stock has traded between $1.21 and $1.35 so far today. Volume today is light. So far 949,750 shares have traded compared to average volume of 6,452,500 shares. WebMar 31, 2024 · RECURSION PHARMACEUTICALS, INC. : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information Nasdaq: RXRX Nasdaq RECURSION PHARMACEUTICALS, INC. eer40 ボビン https://margaritasensations.com

Recursion Pharmaceuticals - Crunchbase Company Profile

WebJul 13, 2024 · SALT LAKE CITY, July 13, 2024 - Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board (TAB), chaired by Joseph Miletich, MD, PhD. … WebFeb 17, 2024 · Recursion Pharmaceuticals completed its IPO in 2024, raising >$500m. The company is promising to revolutionize drug discovery with AI - although the evidence for … WebApr 11, 2024 · The 15 analysts offering price forecasts for Recursion Pharmaceuticals, have a median target of 19.93, with a high estimate of 37.00 and a low estimate of 7.00. The median estimate represents a... eeprom データ化け 原因

Which Is a Better Investment, Denali Therapeutics Inc or Recursion …

Category:Analysts Offer Insights on Healthcare Companies: United Therapeutics …

Tags:Recursion therapeutics stock

Recursion therapeutics stock

IPO: Recursion Pharmaceuticals Leverages Therapeutics Discovery With …

WebRecursion The industrial revolution of drug discovery is here. LEARN HOW › Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology …

Recursion therapeutics stock

Did you know?

WebMar 28, 2024 · Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion OS, a platform built … WebApr 10, 2024 · Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral ...

WebRecursion Pharmaceuticals started at buy with $31 stock price target at BofA Securities May. 11, 2024 at 9:44 a.m. ET by Tomi Kilgore Recursion Pharmaceuticals started at … WebWe collaborate with leading biopharmaceutical companies to broadly explore diverse disease domains and rapidly identify novel therapeutic candidates. Roche & Genentech In December 2024, we entered into a multi-year, strategic collaboration with Roche and Genentech in key areas of neuroscience and an oncology indication.

WebDiscover historical prices for RXRX stock on Yahoo Finance. View daily, weekly or monthly format back to when Recursion Pharmaceuticals, Inc. stock was issued. WebApr 10, 2024 · SVB Securities analyst Mani Foroohar reiterated a Hold rating on Recursion Pharmaceuticals (RXRX - Research Report) on February 27 and set a price target of $9.00. …

WebFind the latest Tango Therapeutics, Inc. (TNGX) stock quote, history, news and other vital information to help you with your stock trading and investing.

WebApr 13, 2024 · Denali Therapeutics (DNLI) In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Denali Therapeutics, with a price target of $50.00.The company’s shares closed ... eepromとは何かWebApr 11, 2024 · According to analysts, Recursion Pharmaceuticals's stock has a predicted upside of 36.20% based on their 12-month price targets. What analysts cover Recursion … eeprom norフラッシュWeb1. the cause of the disease is well-defined. 2. there is high unmet need, there are no approved therapies, or there are significant shortcomings with existing treatment paradigms. Expanded Access Policy Clinical Trial Transparency. eeprom フラッシュメモリ 比較WebApr 11, 2024 · Recursion Pharmaceuticals, stock has received a consensus rating of hold. The average rating score is and is based on 5 buy ratings, 10 hold ratings, and 0 sell ratings. eerg オリックスWebWe would like to show you a description here but the site won’t allow us. eepromとは わかりやすくWebRXRX Recursion Pharmaceuticals Inc - Ordinary Shares - Class A 559 Watch $6.65 $0.20 (3.10%) Today $6.52 0.13 (1.96%) After Hours Market Cap $1.27B Volume (M) 907,850.00 … ee-rq50-wa ヨドバシWebApr 10, 2024 · Price Why Recursion Pharmaceuticals Inc’s (RXRX) Stock Is Down 7.35% As of Thursday, February 16, Recursion Pharmaceuticals Inc’s RXRX share price has dipped by 7.35%, which has investors questioning if this is right time to buy. Sean Murphy Price Why Recursion Pharmaceuticals Inc’s (RXRX) Stock Is Up 4.39% ee-rr35-wa ヨドバシ